首頁 > 市場調查報告書 > 醫療設備

導管心血管設備

市場調查報告書

商品編碼

1542863

全球馬凡氏症候群治療市場 - 2024-2031

Global Marfan Syndrome Treatment Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

全球馬凡氏症候群治療市場於2023年達到2.035億美元，預計到2031年將達到3.126億美元，在2024-2031年預測期間複合年成長率為5.6%。

馬凡氏症候群是一種遺傳性疾病，會影響結締組織，即支撐和固定器官和體內其他結構的纖維。馬凡氏症候群最常影響心臟、眼睛、血管和骨骼。治療方法取決於受影響的身體部位，可能包括藥物、其他療法和手術來控制病情及其併發症。治療和手術方面的研究和進步使馬凡氏症患者能夠過著長壽、有生產力的生活。

市場動態：

驅動程式和限制

研究與開發的崛起

研發的成長是預測期內幫助整個市場成長的主要促進因素之一。研究和開發正在透過新穎的成像方法、治療標靶和機器學習模型來推進對馬凡氏症候群的理解和治療。

例如，2023 年 5 月的一項研究表明，纖維連接蛋白有可能治療馬凡氏症候群 (MFS) 患者的主動脈瘤。研究表明，MFS 中的整合素 a5B1 負責放大發炎反應，這為主動脈瘤提供了一種新的治療方法。

與此症候群相關的副作用

馬凡氏症候群影響身體的不同部位，可能會出現其他問題和併發症，包括身體主動脈（主動脈）擴大（動脈瘤），當主動脈壁變弱和凸出時就會發生這種情況。如果主動脈壁撕裂或破裂，這是危及生命的緊急情況。白內障是眼睛水晶體中的混濁區域。當脊髓周圍的組織變弱和伸展時，就會發生硬腦膜擴張。

細分市場分析

全球馬凡氏症候群治療市場根據治療類型、給藥途徑、最終用戶和地區進行細分。

主動脈擴張治療類型細分市場約佔馬凡氏症候群治療市佔率的37.3%

治療型節段的主動脈擴張約佔37.3%。馬凡氏症候群是一種相對常見的結締組織遺傳性疾病，影響許多器官系統，但最嚴重的併發症是主動脈瘤和夾層。有多種藥物和手術方法可用於治療心血管併發症。

例如，2022 年8 月，馬凡基金會稱，對1442 名馬凡氏症參與者進行的七項全球臨床試驗的薈萃分析發現，血管緊張素受體阻斷劑（ARB）可顯著降低患者主動脈根部擴大的比率。研究發現，氯沙坦和厄貝沙坦等 ARB 藥物即使對於已經服用 BETA 受體阻斷劑的患者也有效。在具有致病性 FBN1 基因突變的患者中，降低發生率的效果尤其顯著，為此效果提供了生物學支持。

市場地域佔有率

預計北美在整個預測期內將佔據總市場佔有率的 38.4% 左右

由於美國馬凡氏症候群患病率上升、治療方案的進步、FDA 批准、新產品推出等因素，預計北美在整個預測期內將佔據約 38.4% 的市場佔有率幫助該地區在預測期內實現成長。

例如，在威斯康辛州兒童醫院，美國估計有 5 萬人患有馬凡氏症候群（即每 5,000 人中就有 3 人）。馬凡氏症候群在男性和女性中的發生率相同，並且在所有種族和族裔群體中的發病率也相同。其發生率為兩萬分之一的活產嬰兒。

Marfan syndrome is an inherited disorder that affects connective tissue the fibres that support and anchor the organs and other structures in the body. Marfan syndrome most commonly affects the heart, eyes, blood vessels, and skeleton. Treatment varies depending on the area of the body affected and may include medications, other therapies, and surgery to manage the condition and its complications. Research and advances in treatments and surgeries allow people with Marfan syndrome to live long, productive lives.

Market Dynamics: Drivers & Restraints

Rise in research and development

The rise in research and development is one of the major driving factors that help the overall market to grow during the forecast period. Research and development are advancing the understanding and treatment of Marfan syndrome through novel imaging methods, therapeutic targets, and machine-learning models.

For instance, in May 2023, a study suggested that fibronectin can potentially treat aortic aneurysms in individuals with Marfan Syndrome (MFS). The research indicates that integrin a5B1 in MFS is responsible for amplifying inflammatory responses, suggesting a new treatment approach for aortic aneurysms.

Side effects associated with the syndrome

Marfan syndrome affects different areas of the body, other problems and complications can develop, including, enlargement (aneurysm) of the main artery in the body (aorta), which happens when the wall of the aorta weakens and bulges. It is a life-threatening emergency if the wall of the aorta tears or ruptures. Cataracts are cloudy areas in the lens of the eye. Dural ectasia happens when the tissue that surrounds the spinal cord weakens and stretches.

Market Segment Analysis

The global Marfan syndrome treatment market is segmented based on treatment type, route of administration, end-user, and region.

The aortic dilation from the treatment type segment accounted for approximately 37.3% of the Marfan syndrome treatment market share

The aortic dilation from the treatment type segment accounted for approximately 37.3%. Marfan syndrome is a relatively common heritable disorder of connective tissue that affects numerous organ systems, but the most severe complication is aortic aneurysm and dissection. A variety of medical and surgical approaches are available for managing the cardiovascular complications.

For instance, in August 2022, according to the Marfan Foundation, a meta-analysis of seven global clinical trials involving 1442 participants with Marfan syndrome found that angiotensin receptor blockers (ARBs) significantly reduce the rate of aortic root enlargement in patients. The study found that ARBs, such as losartan and irbesartan, were effective even among those already taking beta-blockers. The rate-reducing effect was particularly significant among patients with a disease-causing FBN1 gene mutation, providing biological support for the effect.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the rise in the prevalence of Marfan syndrome in the United States, advancement in treatment options, FDA approvals, novel product launches, and other factors help the region to grow during the forecast period.

For instance, in Children's Wisconsin, an estimated 50,000 people in the United States have Marfan syndrome (or three out of every 5,000 people). Marfan syndrome occurs in equal numbers in males and females and also appears equally in all races and ethnic groups. It occurs in one in 20,000 live births.

Market Segmentation

By Treatment Type

Aortic Dilation

Beta Blocker

Calcium Channel Blocker

ACE Blocker

Aortic root replacement

Valve sparing root replacement

Complex aortic surgery for dissections and aneurysms

Others

By Route of Administration

Oral

Parenteral

Others

By End-User

Hospitals

Clinics

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Mesa Science Associates Inc., Merck & Co. Inc., Aurobindo Pharma USA, Teva Pharmaceuticals, Lupin Pharmaceuticals, Inc., and AdvaCare Pharma among others.

Key Developments

In November 2023, a Pune team of eye surgeons at a city hospital successfully restored normal vision in a 35-year-old woman living with Marfan syndrome, a genetic disorder affecting connective tissue the fibers that support and anchor organs and other structures in the human body.

Why Purchase the Report?

To visualize the global Marfan syndrome treatment market segmentation based on treatment type, route of administration, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the Marfan syndrome treatment market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global Marfan syndrome treatment market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in research and development
  - 4.1.1.2. Rise in the prevalence of chronic diseases
- 4.1.2. Restraints
  - 4.1.2.1. Side effects associated with the syndrome
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Treatment Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Aortic Dilation*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Beta Blocker
6.4. Calcium Channel Blocker
6.5. ACE Blocker
6.6. Aortic root replacement
6.7. Valve sparing root replacement
6.8. Complex aortic surgery for dissections and aneurysms
6.9. Others

7. By Route of Administration

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
7.4. Others

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Clinics
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Mesa Science Associates Inc *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Merck & Co. Inc
11.3. Aurobindo Pharma USA
11.4. Teva Pharmaceuticals
11.5. Lupin Pharmaceuticals, Inc
11.6. AdvaCare Pharma (*LIST NOT EXHAUSTIVE)